Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
Six months of apalutamide combined with ADT increases 5-year metastasis-free survival to 78.2% in high-risk localized prostate cancer patients.
- Why it matters: Improving long-term outcomes for high-risk prostate cancer patients remains a challenge, and current treatments may not sufficiently prevent metastasis and death.
- What they did: The phase III PROTEUS trial compared apalutamide plus ADT versus perioperative ADT alone in patients with high-risk localized prostate cancer, measuring metastasis-free survival at 5 years.
- The result: Patients receiving apalutamide plus ADT showed a 4.7 percentage point higher 5-year metastasis-free survival, suggesting this combination may offer a new SOC for some prostate cancers.
The findingWhy it mattersWhat they didThe result
- In the news